India, Oct. 22 -- The Department of Pharmaceuticals, central government, in a press release on Thursday announced approval of a 30% cap on margins charged on the supply and sale of non-scheduled anti-cancer medicines, a measure it expects to reduce prices by up to 70% and help cancer patients save ₹2,500 crore annually.
The Department of Pharmaceuticals said the move would extend price protection to non-scheduled cancer medicines, which are currently outside the list of drugs subject to government-fixed ceiling prices.
New margin mechanism
Under the new mechanism, margins on non-scheduled anti-cancer medicines will be limited to 30% of their maximum retail price.
The Department of Pharmaceuticals said the decision followed an analysis b...